Updated:
AstraZeneca US
AstraZeneca Trust for Defined Benefit Pension Plans operates as the qualified plan for US employees of the global biopharmaceutical company. It supplies...
AstraZeneca US
AstraZeneca Trust for Defined Benefit Pension Plans operates as the qualified plan for US employees of the global biopharmaceutical company. It supplies retirement, death and disability coverage from its Wilmington base. The plan allocates 24 percent to private equity alongside public equities, fixed income and real assets. Confirmed holdings include positions through MedImmune Ventures in Pandion Operations and Aslan Pharmaceuticals. Geographic reach centers on North America with manufacturing exposure in Virginia, Maryland and Texas. Assets total $835 million. The plan uses WTW and BlackRock as external managers. No recent operational events specific to the pension vehicle appear in available records. Corporate ownership by AstraZeneca PLC supplies the structural link that separates plan governance from the parent operating company.
General information
Firm type
Pension Fund
Location
Region
North America
Country
United States
City
Wilmington
Corporate office
1800 Concord Pike, Wilmington, DE 19850, United States
Principals
Pascal Soriot
Global CEO and Executive Director
Rick R. Suarez
Senior Vice President, US President and Head of the US BioPharmaceuticals Business Unit
Sector focus
Frequently asked questions
Who runs investment decisions at AstraZeneca US?
Global leadership under Pascal Soriot sets overall direction while external managers including BlackRock and WTW execute day-to-day portfolio decisions for the pension plan.
Does AstraZeneca US participate in fund commitments or only direct deals?
The plan commits to private equity funds and holds direct real estate assets such as the North Campus leaseback and multiple manufacturing facilities.
What investment stages does AstraZeneca US typically target?
The plan targets a balanced mix that includes early-stage venture through MedImmune Ventures alongside later-stage and buyout private equity exposure.
Where does the underlying wealth come from?
Assets derive from corporate contributions by AstraZeneca Pharmaceuticals LP to fund employee defined benefit obligations.
How is AstraZeneca US related to AstraZeneca PLC?
The Wilmington plan is a wholly owned subsidiary pension vehicle of the UK-listed parent company AstraZeneca PLC.
What is AstraZeneca US known posture on co-investments alongside external GPs?
The plan has executed co-investments through its MedImmune Ventures arm in biotechnology companies including Ardea Biosciences.
Does AstraZeneca US maintain philanthropic structures?
Separate foundations including the AstraZeneca Foundation and Alexion Charitable Foundation handle US health-equity giving outside the pension plan.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on pension funds?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: